Circadian rhythm of serum interleukin-6 in rheumatoid arthritis. 1994

N G Arvidson, and B Gudbjörnsson, and L Elfman, and A C Rydén, and T H Tötterman, and R Hällgren
Department of Medicine, University Hospital, Uppsala, Sweden.

OBJECTIVE To test the hypothesis of a diurnal variation in circulating levels of interleukin-6 (IL-6) and/or tumour necrosis factor-alpha (TNF-alpha) in rheumatoid arthritis and other inflammatory connective tissue diseases. METHODS Serum levels of IL-6 and TNF-alpha were measured at three hour intervals from 7:30 to 22:30 in 48 patients with different rheumatic diseases as well as ten healthy controls. In four of the patients with rheumatoid arthritis, serum IL-6 levels were measured before and after one week of treatment with prednisolone 15-20 mg daily. RESULTS IL-6 and TNF-alpha could not be detected in serum from healthy controls. However, serum IL-6 levels were substantially increased in patients with rheumatoid arthritis. Furthermore, patients with rheumatoid arthritis showed a statistically significant circadian variation in levels of IL-6. Peak values appeared in the morning and low values in the afternoon and evening. In contrast, levels were low and stable in other connective tissue diseases. Levels of TNF-alpha were low in patients with rheumatoid arthritis and high in patients with other connective tissue diseases, but without circadian rhythm. After treatment with prednisolone, levels of serum IL-6 decreased significantly, but the circadian rhythm remained. CONCLUSIONS The circadian rhythm of circulating IL-6 might correspond to the circadian rhythm of symptoms in rheumatoid arthritis. The diurnal variation of IL-6, and possibly other cytokines, might explain the conflicting results previously reported on the inter-relationship between circulating IL-6 levels and disease activity in rheumatoid arthritis.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D002940 Circadian Rhythm The regular recurrence, in cycles of about 24 hours, of biological processes or activities, such as sensitivity to drugs or environmental and physiological stimuli. Diurnal Rhythm,Nyctohemeral Rhythm,Twenty-Four Hour Rhythm,Nycthemeral Rhythm,Circadian Rhythms,Diurnal Rhythms,Nycthemeral Rhythms,Nyctohemeral Rhythms,Rhythm, Circadian,Rhythm, Diurnal,Rhythm, Nycthemeral,Rhythm, Nyctohemeral,Rhythm, Twenty-Four Hour,Rhythms, Circadian,Rhythms, Diurnal,Rhythms, Nycthemeral,Rhythms, Nyctohemeral,Rhythms, Twenty-Four Hour,Twenty Four Hour Rhythm,Twenty-Four Hour Rhythms
D003240 Connective Tissue Diseases A heterogeneous group of disorders, some hereditary, others acquired, characterized by abnormal structure or function of one or more of the elements of connective tissue, i.e., collagen, elastin, or the mucopolysaccharides. Connective Tissue Disease,Disease, Connective Tissue,Diseases, Connective Tissue
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001168 Arthritis Acute or chronic inflammation of JOINTS. Oligoarthritis,Polyarthritis,Arthritides,Oligoarthritides,Polyarthritides
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis

Related Publications

N G Arvidson, and B Gudbjörnsson, and L Elfman, and A C Rydén, and T H Tötterman, and R Hällgren
April 2001, Metabolism: clinical and experimental,
N G Arvidson, and B Gudbjörnsson, and L Elfman, and A C Rydén, and T H Tötterman, and R Hällgren
July 2020, International journal of molecular sciences,
N G Arvidson, and B Gudbjörnsson, and L Elfman, and A C Rydén, and T H Tötterman, and R Hällgren
May 2006, Current opinion in rheumatology,
N G Arvidson, and B Gudbjörnsson, and L Elfman, and A C Rydén, and T H Tötterman, and R Hällgren
April 1993, The Journal of rheumatology,
N G Arvidson, and B Gudbjörnsson, and L Elfman, and A C Rydén, and T H Tötterman, and R Hällgren
January 2014, BioMed research international,
N G Arvidson, and B Gudbjörnsson, and L Elfman, and A C Rydén, and T H Tötterman, and R Hällgren
March 2013, Drugs,
N G Arvidson, and B Gudbjörnsson, and L Elfman, and A C Rydén, and T H Tötterman, and R Hällgren
October 1994, Journal of interferon research,
N G Arvidson, and B Gudbjörnsson, and L Elfman, and A C Rydén, and T H Tötterman, and R Hällgren
October 2008, Current rheumatology reports,
N G Arvidson, and B Gudbjörnsson, and L Elfman, and A C Rydén, and T H Tötterman, and R Hällgren
January 1998, Mediators of inflammation,
N G Arvidson, and B Gudbjörnsson, and L Elfman, and A C Rydén, and T H Tötterman, and R Hällgren
January 1984, Terapevticheskii arkhiv,
Copied contents to your clipboard!